Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QNB CORP.QNBC · Entity 6022 | EVP Chief Lending Officer | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QNB CORP.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,842.881 |
Reported balance
After 2026-02-13 transaction · row 1
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 750 · Balance 16,842.881 F1: Restricted Stock Award |
| Performance-based restricted stock awardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-02-13 | Direct | 250 |
Reported balance
After 2026-02-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-13 · Grant · Acquired 250 · Balance 250 |
| Performance-based restricted stock awardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-02-13 | Direct | 250 |
Reported balance
After 2026-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-13 · Grant · Acquired 250 · Balance 250 |
| Performance-based restricted stock awardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-02-13 | Direct | 250 |
Reported balance
After 2026-02-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-13 · Grant · Acquired 250 · Balance 250 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.26 · Expires 2027-02-15 | Direct | 3,500 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 3,500 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.51 · Expires 2033-02-15 | Direct | 700 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 700 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.51 · Expires 2033-02-15 | Direct | 700 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 700 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.51 · Expires 2033-02-15 | Direct | 700 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 700 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.51 · Expires 2033-02-15 | Direct | 700 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 700 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.51 · Expires 2033-02-15 | Direct | 700 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 700 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2034-02-15 | Direct | 600 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 600 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2034-02-15 | Direct | 600 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 600 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2034-02-15 | Direct | 600 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 600 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2034-02-15 | Direct | 600 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 600 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.40 · Expires 2034-02-15 | Direct | 600 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 600 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-14 | Direct | 860 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 860 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-14 | Direct | 860 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 860 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-14 | Direct | 860 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 860 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-14 | Direct | 860 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · Balance 860 |
| Common Stock(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.50 · Expires 2035-02-14 | Direct | 860 |
Reported balance
Holding disclosure · report date 2026-02-13 · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · Balance 860 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Award
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2016 Filed Jan 17, 2017 16:31 UTC | QNB CORP. QNBC · Entity 6022 | PurchaseCommon Stock | 68 | $26.73 | $1,817.64 |
DisclosureSEC source: 0001384860-17-000009 · primary_doc.xml · nonDerivative · entry 2 OREZEHOSKI SCOTT G · CIK 0001226333 · EVP/Chief Lending Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,610.585 F2 · kind: Employee Stock Purchase Plan Acquisition Read SEC document |
| March 25, 2016 Filed Jan 17, 2017 16:31 UTC | QNB CORP. QNBC · Entity 6022 | PurchaseCommon Stock | 110.0478 | $28.44 | $3,129.76 |
DisclosureSEC source: 0001384860-17-000009 · primary_doc.xml · nonDerivative · entry 1 OREZEHOSKI SCOTT G · CIK 0001226333 · EVP/Chief Lending Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,542.585 F1 · kind: Dividend Reinvestment Plan Acquisition Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.